National Asset Management, Inc. Royalty Pharma PLC Transaction History

National Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$27.46 - $31.33 $440,733 - $502,846	16,050 New	16,050 $487,000
Q3 2023 Dec 01, 2023	SELL	$26.26 - $31.38 $174,629 - $208,677	-6,650 Reduced 29.3%	16,050 $435,000
Q2 2023 Jul 27, 2023	BUY	$29.6 - $36.56 $267,880 - $330,868	9,050 Added 66.3%	22,700 $697,000
Q1 2023 May 17, 2023	SELL	$32.77 - $39.4 $180,235 - $216,700	-5,500 Reduced 28.72%	13,650 $491,000
Q4 2022 Feb 21, 2023	SELL	$39.17 - $44.04 $117,510 - $132,120	-3,000 Reduced 13.54%	19,150 $756,000
Q3 2022 Nov 14, 2022	BUY	$39.88 - $44.65 $338,980 - $379,525	8,500 Added 62.27%	22,150 $890,000
Q2 2022 Aug 12, 2022	BUY	$37.53 - $44.22 $78,813 - $92,862	2,100 Added 18.18%	13,650 $574,000
Q1 2022 May 02, 2022	SELL	$37.46 - $42.44 $536,801 - $608,165	-14,330 Reduced 55.37%	11,550 $450,000
Q4 2021 Jan 28, 2022	SELL	$35.17 - $42.48 $330,598 - $399,311	-9,400 Reduced 26.64%	25,880 $1.03 Million
Q3 2021 Nov 16, 2021	BUY	$36.14 - $42.24 $1.28 Million - $1.49 Million	35,280 New	35,280 $1.28 Million

398

291M

305K

138K

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $12.3B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.